Anesthesia in Pacemaker Implantation and Benign Prostatic Hyperplasia

How sedation, opioids, and anticholinergic drugs administered during cardiac device implantation precipitate acute urinary retention in men with BPH — and what the 2025 evidence tells us about prevention.

Acute urinary retention (AUR) is a well-documented complication of cardiac implantable electronic device (CIED) procedures in men with benign prostatic hyperplasia, even though pacemaker implantation typically uses only local anesthesia plus moderate sedation. The mechanism is not the pacemaker itself, nor the local lidocaine — it is the cocktail of peri-procedural drugs that act on the detrusor muscle, the bladder neck, and the central micturition reflex.

For the cardiologist, the electrophysiologist, and the anesthesia provider working in the EP lab, recognizing this risk is essential. The patient population presenting for pacemaker implantation overlaps almost perfectly with the demographic at highest risk for BPH-related urinary complications: men over 65, often with prior lower urinary tract symptoms, frequently taking medications that further compromise voiding.

Mechanisms: Why Sedation Triggers Retention

The peri-procedural drugs — not the pacemaker hardware or the surgical access — drive AUR risk. Each agent contributes through a different physiologic pathway:

Sedatives

Midazolam, fentanyl, and propofol reduce detrusor contractility and blunt the micturition reflex via central effects on the pontine micturition center. Even short-acting agents at moderate doses meaningfully suppress the coordinated voiding response in elderly men.

Anticholinergic exposure

Anticholinergic drugs — atropine, glycopyrrolate, scopolamine, diphenhydramine, and to a lesser extent ondansetron — worsen detrusor hypocontractility and increase outlet resistance via α-adrenergic tone. In an EP lab, the most common exposure is intra-procedural atropine or glycopyrrolate given for vasovagal episodes during pocket creation, lead manipulation, or sheath insertion.

Opioids

Fentanyl and similar agents suppress the parasympathetic-mediated voiding reflex and increase internal sphincter tone. The effect is dose-dependent, and cumulative boluses across a long procedure compound the risk.

Positioning and fluids

Supine positioning with procedural IV fluids distends the bladder beyond its functional capacity. In a man with already elevated post-void residuals, this is often the precipitating event that converts a compensated system into acute retention.

Incidence in EP-Lab Cohorts

Reported AUR rates after CIED implantation in men over 65 with known BPH range from approximately 5% to 15% in published series, with higher rates associated with longer procedures and cumulative opioid and benzodiazepine dosing.

The most informative recent peri-procedural data actually come from atrial fibrillation ablation cohorts rather than pacemaker trials, since POUR is rarely tracked as an endpoint in CIED studies:

The signal across these datasets is consistent: fluid load, procedural duration, and anticholinergic exposure matter more than the catheter or the access site.

The 2025 Atropine Signal

The most clinically actionable recent finding comes from a 2025 multicenter analysis published in Circulation: Arrhythmia and Electrophysiology: "Incidence and Predictors of Acute Urinary Retention After Atrial Fibrillation Pulsed Field Ablation: A Word of Caution on Routine Atropine Administration."

The companion paper by Vetta and colleagues in JACC: Clinical Electrophysiology (2025) compared glycopyrrolate 0.2 mg IV, atropine 1 mg IV, and no anticholinergic for vagal-reaction prophylaxis during pulsed field ablation across four centers. The mechanism behind the AUR signal is exactly what the physiology predicts: muscarinic blockade of the detrusor superimposed on already-compromised BPH bladder dynamics.

A single 1 mg atropine bolus in a 75-year-old man with a 50 mL prostate and a baseline post-void residual of 80 mL is plausibly the difference between voiding normally and going home with a Foley catheter.

This matters disproportionately for the CIED population because atropine and glycopyrrolate are routinely available on every EP-lab medication tray and are frequently administered for vasovagal episodes during pacemaker implantation.

Tamsulosin Prophylaxis: Mixed Evidence

The peri-operative α-blocker literature does not support a blanket recommendation for tamsulosin prophylaxis:

• A 2022 meta-analysis of 14 RCTs (2,221 patients) concluded that prophylactic tamsulosin reduces POUR, with younger patients (under 50) appearing to benefit more — but with a higher rate of adverse events in the active drug group.
• A 2023 commentary refined this: prophylactic tamsulosin under general anesthesia did not reduce POUR, but it may help under spinal anesthesia. The timing and route of administration matter.
• A randomized trial in elective abdominal surgery (158 enrolled) found no difference in POUR between groups (26% tamsulosin vs. 31% placebo, P = 0.49). Epidural usage, open surgery, and age under 50 were the actual risk factors identified.

For an EP-lab implant performed under MAC sedation — without general anesthesia, spinal, or epidural — the strongest evidence-based interventions are not pharmacologic prophylaxis but procedural.

Practical Prevention Protocol

Drawing on the available evidence, the following peri-procedural strategy minimizes AUR risk in BPH patients undergoing pacemaker or CIED implantation:

1. Avoid routine anticholinergic prophylaxis. Reserve atropine and glycopyrrolate for clinically necessary vagal events, not preventive dosing. The 2025 PFA data are the cleanest demonstration that anticholinergics alone, in an EP-lab population, precipitate AUR.
2. Continue chronic α-blockers. Patients on stable tamsulosin or alfuzosin should not have these held the morning of the procedure. There is no compelling reason to interrupt chronic therapy.
3. Restrict IV fluids. The AF ablation data demonstrate a clear dose-response relationship between volume administered and bladder distention.
4. Minimize cumulative fentanyl and midazolam. Opioid-sparing protocols — including dexmedetomidine-based sedation — reduce both detrusor suppression and respiratory adverse events.
5. Pre-procedure void. A simple, high-yield maneuver: ensure the patient empties the bladder immediately before transfer to the EP table.
6. Early ambulation post-procedure as soon as the venous access site permits.

Bottom Line

The two most under-recognized precipitants of post-implant AUR in BPH patients are intra-procedural anticholinergic boluses and excessive crystalloid administration — not the local anesthetic or sedation per se. Recognition of this distinction allows targeted prevention with no added cost, no added pharmacology, and meaningful reduction in a complication that prolongs admission and exposes patients to catheter-associated infection risk.